000 02929cam a2200349 a 4500
003 EG-GiCUC
005 20250223031429.0
008 160223s2015 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.19.04.Ph.D.2015.Ah.P
100 0 _aAhmed Magdy Rabea
245 1 4 _aThe predictive value of fats (fragile-site associated tumor suppressor) gene expression on the sensitivity of cisplatin in advanced non-small cell lung cancer /
_cAhmed Magdy Rabea ; Supervised Rabab Mohamed Gaafar , Ola Mohamed Khorshid , Ayman Abdelsamie Gaber
246 1 5 _aفى الحالات المتقدمة لسرطان الرئة ذو الخلايا الغير صغيرة المعالجة بعقار السيسبلاتين (Fragile-Site Associated Tumor Suppressor) استخدام الجين
260 _aCairo :
_bAhmed Magdy Rabea ,
_c2015
300 _a132 P. :
_bcharts ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Medical Oncology
520 _aPatients and methods: A prospective longitudinal study has been conducted in NCI (National Cancer Institute) medical oncology department in outpatient setting, in the period between June 2012 and July 2014. The study included 70 patients with pathologically proven advanced (stage IIIB and IV) non-small cell lung cancer (NSCLC) treated with cisplatin and gemcitabine. FATS gene expression was measured before starting the treatment. The primary end point was overall response rate (ORR) while the secondary end point was progression free survival (PFS) and overall survival (OS).Results: Seventy patients were assessed and included in the trial. Thirteen patients achieved partial response while 13 patients achieved stable disease and the rest had a progressive disease. The overall response rate was statistically significant (p-value 0.031) for the high FATS expression group. The median PFS was 4.1 months (95% CI 2.1-6.2) in the low expression group and 3.8 months (95% CI 3.3-4.3) in the high expression group (p-value 0.442) while median OS was 6.9 months (95% CI 5.4-8.3) in the high expression group and 4.5 months (95% CI 3.7-5.3) in the low expression group (p-value 0.031)Conclusion: The expression of the FATS gene can have an implication on the response to cisplatin and the overall survival. This opens the opportunity that FATS gene can be used as a predictive marker for NSCLC patients receiving cisplatin and gemcitabine chemotherapy
530 _aIssued also as CD
653 4 _aCisplatin
653 4 _aFATS
653 4 _aNSCLC
700 0 _aAyman Abdel Samie Gaber ,
_eSupervisor
700 0 _aOla Mohamed Khorshid ,
_eSupervisor
700 0 _aRabab Mohamed Gaafar ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aEnas
_eCataloger
905 _aNazla
_eRevisor
942 _2ddc
_cTH
999 _c55154
_d55154